导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.49% | 3362/4773 |
| 近一周 | -2.32% | 3724/5465 |
| 近一月 | -2.30% | 1565/5421 |
| 近一季 | -4.37% | 1802/5231 |
| 近半年 | -3.84% | 2616/4920 |
| 近一年 | -0.75% | 2885/4394 |
| 近两年 | 37.50% | 2007/2954 |
| 近三年 | 22.71% | 1389/2253 |
| 成立以来 | 77.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.69% 3913/4961 |
5.37% 2884/5312 |
- - |
- - |
| 2025 | 19.16% 2243/4813 |
-0.37% 2221/3635 |
2.38% 1607/4076 |
15.31% 2819/4524 |
1.32% 1421/4813 |
| 2024 | 15.33% 942/3463 |
4.78% 433/2808 |
-1.50% 1069/3014 |
14.78% 1910/3129 |
-2.65% 2150/3463 |
| 2023 | -8.25% 992/2656 |
3.78% 1128/2280 |
-2.95% 722/2385 |
-2.87% 774/2515 |
-6.21% 1669/2655 |
| 2022 | -18.17% 671/2207 |
-12.39% 607/1919 |
8.20% 379/2016 |
-14.89% 1168/2113 |
1.43% 1270/2208 |
| 2021 | -4.66% 956/1822 |
-4.50% 868/1255 |
5.31% 818/1330 |
-4.52% 715/1466 |
-0.71% 1268/1822 |
| 2020 | 41.92% 280/1250 |
-7.53% 549/1028 |
16.01% 463/1067 |
16.78% 134/1164 |
13.29% 372/1184 |
| 2019 | 40.07% 260/1092 |
27.63% 340/739 |
0.73% 153/788 |
1.92% 344/850 |
6.89% 528/918 |
| 2018 | -22.54% 244/834 |
- - |
-6.41% 116/631 |
-1.79% 263/660 |
-12.01% 394/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 招商沪深300指数增强C VS. 长安沪深300非周期A(740101) |